New COPD drug candidate AZD6793 passes first safety tests in humans
NCT ID NCT05662033
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new drug called AZD6793 in 93 people to see if it is safe and how the body processes it. The study included healthy volunteers and people with moderate to severe COPD. The main goal was to check for side effects and measure drug levels in the blood, not to treat the disease. This research helps decide if the drug should move to larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Harrow, HA1 3UJ, United Kingdom
-
Research Site
Wythenshawe, M23 9QZ, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gentle exercise with leg cuffs may offer a new path to rehab for COPD patients
- Could treating sleep apnea during a COPD hospital stay keep patients out of the hospital?
- HIV and lungs: botswana study seeks clues to COPD risk
- Ultrasound of the lungs may unmask hidden heart failure in COPD patients
- Could pedaling backward help heart and lung patients get stronger?
- Smart home tech could ease COPD care